{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-042877","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2021-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.425280+00:00","generated_at":"2026-06-29T17:01:04.129668+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Finch transfers FIN-524 ulcerative colitis program to Takeda for clinical development","bullets":["Amendment (Aug 9, 2021) transfers primary development & regulatory responsibility for FIN-524/TAK-524 to Takeda ahead of Phase 1.","Finch received $10M upfront & $4M in milestones; eligible for up to $176M additional plus mid-to-high single-digit royalties.","Finch will provide technical support through Phase 1; joint Crohn's disease discovery continues.","TAK-524 is an orally administered consortia candidate targeting ulcerative colitis via immune modulation."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-042877","json":"https://secwatch.observer/filing/0001564590-21-042877.json","markdown":"https://secwatch.observer/filing/0001564590-21-042877.md","text":"https://secwatch.observer/filing/0001564590-21-042877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000156459021042877/0001564590-21-042877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000156459021042877/fnch-8k_20210810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T17:01:04.129668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}